| Literature DB >> 27086305 |
A Kedziora1, K Korzekwa2, W Strek3, A Pawlak2, W Doroszkiewicz2, G Bugla-Ploskonska2.
Abstract
The scope of this study included the preparation of silver nanoforms with high antimicrobial efficacy, low cost, and ease of application. The term 'silver nanoforms' refers to silver located on the amorphous or crystalline titanium dioxide (TiO2). Silver nanoforms may be used as an alternative to antibiotics in killing bacteria. Pure and silver-incorporated titanium (used as a carrier) was prepared using the sol-gel-modified method. Physical and chemical properties of the samples were described, and the antibacterial activity was indicated using the following strains of bacteria: Staphylococcus aureus, Klebsiella pneumoniae (ESKAPE pathogens), and Escherichia coli. The results have shown that the antibacterial activity of silver nanoforms with amorphous TiO2 is much better than that in the samples based on anatase (crystalline TiO2). The sensitivity of the tested bacteria to silver nanoforms depends on physical and chemical properties of the nanoforms and individual characteristics of the bacteria. For the first time, significant participation of amorphous TiO2 in antibacterial compounds has been described through this study.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27086305 PMCID: PMC4899487 DOI: 10.1007/s00284-016-1034-8
Source DB: PubMed Journal: Curr Microbiol ISSN: 0343-8651 Impact factor: 2.188
Physicochemical description of prepared samples
| Sample | Kind of TiO2 | Size of TiO2 (nm) | Size of silver nanoparticles (nm) | Content of silver (wt%) |
|---|---|---|---|---|
| TiO2 | Amorphous | ≤100 | n/a | n/a |
| TiO2/Ag0 | Amorphous | ≤100 | 20 | 10 |
| TiO2/Ag+ | Amorphous | ≤100 | n/a | 10 |
| TiO2a | Anatase | ≤40 (aggregate) | n/a | n/a |
| TiO2a/Ag0 | Anatase | ≤40 (aggregate) | ≤10 | 1 |
| TiO2a/Ag+ | Anatase | ≤40 (aggregate) | n/a | 1 |
n/a not applicable
Antibiogram of bacterial isolates
| Bacterial isolates | Am | Amc | Cxm | Ctx | Caz | Atm | An | Cip | SXT | Imp | Mem | TZP | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| S | R | R | S | S | S | S | S | S | S | S | S | |||
|
| S | R | R | S | S | S | S | S | S | S | S | S | |||
|
| S | R | R | S | S | S | S | S | S | S | S | S | |||
|
| S | R | R | S | S | S | S | S | S | S | S | S |
S sensitive, R resistant, Am ampicillin, AMC amoxicillin-clavulanic acid, CXM cefuroxime, CTX cefotaxime, CAz ceftazidime, AN amikacin, Ge gentamicin, ATM aztreonamum, CIP ciprofloxacin, Imp imipenem, Mem meropenem, Tzp piperacillin–tazobactam, SXT trimethoprim–sulfamethoxazole, P penicillin, E erytromycin, CC clindamycin, VA vancomycin, FOX cefoxitin
aBacterial isolates, numbered by Medical Laboratory DiaLab
Fig. 1TEM images of amorphous TiO2 (a) and crystalline TiO2 (b)
Surface area (S BET) and pore size get with nitrogen adsorptions
| Sample |
| Pore size (nm) |
|---|---|---|
| TiO2 | 424.0 ± 8.0 | 4 |
| TiO2a | 52.8 ± 0.2 | 22 |
Fig. 2XRD patterns of: a amorphous TiO2, b crystalline TiO2a, c amorphous TiO2/Ag0 and d crystalline TiO2a/Ag0
Fig. 3N2 adsorption and desorption by amorphous TiO2 and crystalline TiO2a
MIC (µg/ml) of amorphous TiO2 doped with silver (TiO2/Ag+ and TiO2/Ag0) with and without UV irradiation
| Bacteria strains | MIC [µg/ml] TiO2/Ag+ | MIC [µg/ml] TiO2/Ag0 | ||
|---|---|---|---|---|
| Without UV | With UV | Without UV | WITH UV | |
|
| 0.05 | 0.05 | 0.4 | 0.4 |
|
| 0.05 | 0.05 | 0.4 | 0.4 |
|
| 0.05 | 0.05 | 0.4 | 0.4 |
|
| 0.05 | 0.05 | 0.4 | 0.4 |
|
| 0.05 | 0.05 | 0.4 | 0.4 |
|
| 0.05 | 0.05 | 0.4 | 0.4 |
|
| 0.05 | 0.05 | 0.4 | 0.4 |
|
| 0.05 | 0.05 | 0.4 | 0.4 |
|
| 0.05 | 0.05 | 0.4 | 0.4 |
|
| 0.05 | 0.05 | 0.4 | 0.4 |
aBacterial isolates
MIC (µg/ml) of anatase doped with silver (TiO2a/Ag+ and TiO2a/Ag0) with and without UV irradiation
| Bacteria strains | MIC (µg/ml) TiO2a/Ag+ | MIC (µg/ml) TiO2a/Ag0 | ||
|---|---|---|---|---|
| Without UV | With UV | Without UV | With UV | |
|
| 0.8 | 0.4 | 25.6 | 12.8 |
|
| 1.6 | 0.8 | 25.6 | 12.8 |
|
| 1.6 | 0.8 | 25.6 | 12.8 |
|
| 1.6 | 0.8 | 25.6 | 12.8 |
|
| 3.2 | 1.6 | 25.6 | 12.8 |
|
| 3.2 | 1.6 | 51.2 | 25.6 |
|
| 1.6 | 0.8 | 51.2 | 25.6 |
|
| 3.2 | 1.6 | 25.6 | 12.8 |
|
| 3.2 | 1.6 | 51.2 | 25.6 |
|
| 3.2 | 1.6 | 51.2 | 25.6 |
aBacterial isolates